Because aging is highly individualized, the best guide to treatment of the
older patient with cancer may be provided by a comprehensive assessment tha
t evaluates such diverse areas as functional status, comorbidity, socioecon
omic conditions, nutrition, polypharmacy, and the presence or absence of ge
riatric syndromes. Aging is further associated with important pharmacologic
changes that involve pharmacokinetics, pharmacodynamics, and the toxicity
profile of the drugs. These changes increase the risk of therapeutic compli
cations partly because of the different behavior of the disease in an older
patient population and partly because of a decreased tolerance to treatmen
t in some older patients.